Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 14/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 12/20 | 0.39 |
| ▸ | MBTD1 | Q05BQ5 | 5/20 | 0.38 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.38 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL409798 | 0.98 | L3MBTL3 (0.41) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| Hydrochloric Acid SCHEMBL14994948 | 0.84 | L3MBTL3 (0.40) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL18702213 | 0.80 | L3MBTL3 (0.42) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| Hydrochloric Acid SCHEMBL28477335 | 0.75 | L3MBTL3 (0.36) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| Hydrochloric Acid SCHEMBL28480488 | 0.75 | L3MBTL3 (0.36) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL38651931 | 0.74 | — | — | |
| SCHEMBL27976017 | 0.72 | L3MBTL3 (0.37) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| Hydrochloric Acid SCHEMBL28480490 | 0.72 | L3MBTL3 (0.38) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| Hydrochloric Acid SCHEMBL31467080 | 0.71 | L3MBTL3 (0.50) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL28880864 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250241940-A1 | MODIFIED ANTISENSE OLIGOMERS FOR EXON INCLUSION IN SPINAL MUSCULAR ATROPHY | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2025-07-31 | — | — | US | disclosed |
| US-12121532-B2 | Modified antisense oligomers for exon inclusion in spinal muscular atrophy | SAREPTA THERAPEUTICS, INC. (US) | 2024-10-22 | — | — | US | disclosed |
| US-20240209363-A1 | OLIGONUCLEOTIDES FOR TREATING EXPANDED REPEAT DISEASES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2024-06-27 | — | — | US | disclosed |
| US-11732259-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11674139-B2 | Oligonucleotides for treating expanded repeat diseases | SAREPTA THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20220127613-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | SAREPTA THERAPEUTICS INC (US) | 2022-04-28 | — | — | US | disclosed |
| US-11225662-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-11208655-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| EP-3858993-A1 | COMPOSITIONS AND METHODS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY AND RELATED DISORDERS | Sarepta Therapeutics, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| EP-3858847-A1 | OLIGONUCLEOTIDES FOR TREATING EXPANDED REPEAT DISEASES | Sarepta Therapeutics, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| US-9161948-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20150073140-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | SAREPTA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | US | disclosed |
| US-20140330006-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | SAREPTA THERAPEUTICS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329772-A1 | INDUCED EXON INCLUSION IN SPINAL MUSCLE ATROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140303238-A1 | OLIGONUCLEOTIDES FOR TREATING EXPANDED REPEAT DISEASES | SAREPTA THERAPEUTICS, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| EP-2785840-A1 | INDUCED EXON INCLUSION IN SPINAL MUSCLE ATROPHY | Sarepta Therapeutics, Inc. (US) | 2014-10-08 | — | — | EP | disclosed |
| US-8779128-B2 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | SAREPTA THERAPEUTICS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| WO-2013082551-A1 | INDUCED EXON INCLUSION IN SPINAL MUSCLE ATROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2013-06-06 | — | — | WO | disclosed |
| US-20120289457-A1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | AVI BIOPHARMA, INC. (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120065169-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065169-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | NSUN2, UPF1, RTCB | L3MBTL3 25/4885L3MBTL1 15/4885MBTD1 1337/4885 |
| US-20240209363-A1 | OLIGONUCLEOTIDES FOR TREATING EXPANDED REPEAT DISEASES | HTT, UPF1, TARDBP | L3MBTL3 87/4885L3MBTL1 112/4885MBTD1 1690/4885 |
| US-12121532-B2 | Modified antisense oligomers for exon inclusion in spinal muscular atrophy | SMN1; SMN2, UPF1, RBM17 | L3MBTL3 522/4885L3MBTL1 480/4885MBTD1 774/4885 |
| US-11208655-B2 | Functionally-modified oligonucleotides and subunits thereof | RTCB, NSUN3, NSUN2 | L3MBTL3 41/4885L3MBTL1 28/4885MBTD1 1562/4885 |
| US-20140330006-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | RTCB, NSUN3, NSUN2 | L3MBTL3 41/4885L3MBTL1 28/4885MBTD1 1562/4885 |
| US-20150073140-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | NSUN2, UPF1, RTCB | L3MBTL3 25/4885L3MBTL1 15/4885MBTD1 1337/4885 |
| US-11674139-B2 | Oligonucleotides for treating expanded repeat diseases | HTT, UPF1, TARDBP | L3MBTL3 87/4885L3MBTL1 112/4885MBTD1 1690/4885 |
| US-20120289457-A1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | SNRPE, SMN1; SMN2, UPF1 | L3MBTL3 134/4885L3MBTL1 36/4885MBTD1 1583/4885 |
| US-20220127613-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | RTCB, NSUN3, NSUN2 | L3MBTL3 41/4885L3MBTL1 28/4885MBTD1 1562/4885 |
| US-11225662-B2 | Peptide oligonucleotide conjugates | SNRPE, SMN1; SMN2, UPF1 | L3MBTL3 134/4885L3MBTL1 36/4885MBTD1 1583/4885 |
| US-20250241940-A1 | MODIFIED ANTISENSE OLIGOMERS FOR EXON INCLUSION IN SPINAL MUSCULAR ATROPHY | SMN1; SMN2, UPF1, RBM17 | L3MBTL3 522/4885L3MBTL1 480/4885MBTD1 774/4885 |
| US-11732259-B2 | Peptide oligonucleotide conjugates | SNRPE, SMN1; SMN2, UPF1 | L3MBTL3 134/4885L3MBTL1 36/4885MBTD1 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.